Welcome to our dedicated page for Health Catalyst news (Ticker: HCAT), a resource for investors and traders seeking the latest updates and insights on Health Catalyst stock.
Health Catalyst, Inc. reports developments tied to healthcare intelligence, data and analytics technology, and professional services for healthcare organizations. Company updates commonly cover operating results, revenue and Adjusted EBITDA guidance, and the use of AI-driven technology and domain expertise to support health systems across cost, clinical, and consumer performance.
Recurring news also includes leadership and board governance changes, shareholder-related board appointments, investor conference participation, and updates on strategic focus areas for its healthcare data platform, analytics applications, implementation, advisory, outsourcing, and improvement services.
Summary not available.
Health Catalyst, Inc. (Nasdaq: HCAT) will release its Q3 2022 operating results on November 8, 2022, after market close. Following the release, a conference call for analysis will occur at 5 p.m. E.T. Participants can join by dialing (800) 225-9448 for U.S. calls or (203) 518-9708 internationally, using conference ID “HCAT Q322.” The call will also be available via a live audio webcast. Health Catalyst focuses on providing data and analytics services to healthcare organizations, leveraging a cloud-based platform analyzing over 100 million patient records to drive healthcare improvements.
On September 14, 2022, Health Catalyst (HCAT) announced the winners of its fourth annual Catalyst Awards during the Healthcare Analytics Summit 2022. The awards honor healthcare organizations for their outstanding use of data and analytics. The University of Kansas Health System received the Flywheel Award for its significant healthcare improvements, including $4.7 million in cost savings and a 39% reduction in 30-day readmissions. Other winners included INTEGRIS Health, WakeMed Health and Hospitals, Indiana University Health, and UnityPoint Health, each recognized for their innovative practices in analytics and patient care.
On September 7, 2022, Health Catalyst (Nasdaq: HCAT) announced new leadership appointments to strengthen its strategic focus areas. Kevin Freeman has been named Chief Growth Officer, while Tarah Neujahr Bryan becomes Chief Marketing Officer. Both will prioritize expanding client relationships. Dave Ross is appointed Chief Technology Officer to enhance data and analytics infrastructure. Effective September 30, 2022, Patrick Nelli transitions to Senior Advisor, and Bryan Hinton completes his tenure. CEO Dan Burton highlighted these changes as pivotal for the company's mission of data-informed healthcare improvements.
Health Catalyst (Nasdaq: HCAT) announced that its CFO, Bryan Hunt, and SVP of Investor Relations, Adam Brown, will participate in the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 11, 2022. They will engage in a fireside chat at 12:00pm ET. The presentation replay will be available on Health Catalyst's investor relations website.
Health Catalyst specializes in data and analytics solutions for healthcare organizations, driven by insights from over 100 million patient records to enhance healthcare decision-making.
Health Catalyst, Inc. (NASDAQ: HCAT) announced the addition of Dr. Melissa Welch as Chief Medical Officer and Dr. Edward Sheen as Chief Population Health Officer. Dr. Welch will support client growth and healthcare improvements, while Dr. Sheen will lead value-based care initiatives. Both new leaders are dedicated to advancing Health Catalyst's mission of data-informed healthcare improvements. Their combined experience in public health and healthcare systems is expected to enhance the company's capabilities and impact in the healthcare sector.
Health Catalyst (Nasdaq: HCAT) announced a $40 million share repurchase program, highlighting their confidence in long-term value. CEO Dan Burton stated the current market does not reflect their true stock value. Repurchases will be discretionary based on market conditions and funded by existing cash, estimated at $403.3 million as of June 30, 2022. The program aims to enhance shareholder value while allowing flexibility in buying patterns.
Health Catalyst (Nasdaq: HCAT) reported Q2 2022 financial results, achieving total revenue of $70.6 million, an 18% year-over-year increase. Technology revenue rose 28% to $45.4 million, while professional services revenue grew 5% to $25.2 million. Despite this, the company revised its full-year revenue and Adjusted EBITDA outlook downwards due to a challenging market environment impacting bookings. However, Health Catalyst remains focused on financial discipline and expects improved Adjusted EBITDA leverage in 2023.
Health Catalyst (Nasdaq: HCAT) partners with LifePoint Health to improve quality in patient care using data analytics technology. This multi-year collaboration aims to enhance LifePoint's National Quality Program by leveraging Health Catalyst's Data Operating System and other analytical tools. The partnership is set to reduce clinical outcome variations and improve decision-making across LifePoint's network of 63 hospitals and additional care sites. Both companies emphasize their commitment to data-driven approaches in healthcare delivery.
Health Catalyst (Nasdaq: HCAT) has announced a multi-year strategic partnership with Akron Children's Hospital, enhancing its analytics platform to improve pediatric care. The collaboration aims to boost patient experiences and operational efficiency using Health Catalyst's advanced analytics tools. Key offerings include the Data Operating System and various analytics applications to support Akron Children's Health Collaborative in enhancing child health and operational outcomes across two hospitals serving over 287,000 children annually.